Eltrombopag (TET2-mutant low-risk MDS/CMML)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-05 — Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations: Early-phase trial evaluation proposes eltrombopag (FDA-approved TPO-RA) as a repurposed agent in low-risk MDS/CMML with TET2 mutations, aiming to improve blood counts while selectively suppressing TET2-mutant clonal growth (trial-early). (novelty: 4)
Open questions
Related
Contributing findings
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
05-jun-2026
novelty 4
per-area 4
introduces